This guide was created to offer you guidance, suggestions, and to connect you with the various resources available on campus.

Ultimately, we encourage you to engage with UCI Applied Innovation as soon as possible.

Suggestions
- Start Discussions Sooner Rather Than Later 4
- Seek Input, Network, and Build Your Team 7
- Develop Your Business Model 9
- Pursue Funding Strategically 9
- Get Counsel On Your Legal Entity 10
- Ensure Compliance 10
- Secure Right to Negotiate/License Agreement 13

Frequently Asked Questions 14-16
Starting a Company: Key Considerations
- Start Up Suggestions: Recap 21
- Building a Team 22-26
  - Choosing Your Role 22
  - Involving a UCI Faculty Member (Conflict of Commitment) 22
  - Involving a UCI Academic Appointee 25
  - Involving Students 25
  - Conflict of Interest Oversight Members for Graduate Students 25
  - Involving Foreign Nationals 26
  - Conflict of Interest (COI) 26
- Analyzing the Company’s Opportunities 28-29
  - Market Size, Dynamics and Potential
  - Competition
  - IP Protection
  - Development Needs/Risks
  - Regulatory Issues
  - Exit Strategies
- Protecting Intellectual Property 30-31
  - Disclosure/Assignment of Patenable Inventions
- Licensing 33
- Building a Funding Strategy 34-35

University Resources 36-37
UCI Commercialization Programs 38
Use of UCI Name and Logo 39
Case Study 40-42
Who to Contact 43
Message from Applied Innovation and Office of Research 44
Quick Contacts Inside Back Cover
As an inventor, multiple paths are possible when commercializing an invention.

The process can be complex. What will be the path?

UCI Applied Innovation can assess your position and guide you through key steps – setting you and the invention up for flexibility, protection, and success at market.
Start Discussions Sooner, Rather than Later. An Early Start Offers the Greatest Flexibility.

It is important to discuss intellectual property (IP) protection and your thoughts about developing and commercializing IP as soon as possible. We encourage you to contact UCI Applied Innovation and the Invention Transfer Group (ITG) early in the process to discuss your business and/or invention.

A Licensing Officer at ITG will work with you to evaluate the opportunity to file a patent application on the invention before it becomes public via publication or presentation. Obtaining a patent after public disclosure may no longer be possible, particularly outside the United States.

Read More:

p.30 Protecting Intellectual Property
p.33 Licensing

Who to Contact:

Licensing Officers @ Applied Innovation:
949-824-2683
http://innovation.uci.edu/about/research-trans-lation/

—Joe Rinehart
Associate Professor of Clinical Anesthesiology
Vice-Chair of Research for Anesthesiology
Founder, Sironis

My colleague and I came to UCI Applied Innovation when we had little more than an idea and a vague gameplan. At every step of the way I was amazed at how helpful and collaborative working with UCI was; you really get the feeling they’re invested in your success.

—Joe Rinehart
Associate Professor of Clinical Anesthesiology
Vice-Chair of Research for Anesthesiology
Founder, Sironis
Seek Input, Network and Build Your Team. Connections Made Today Can Pay Off Tomorrow.

UCI Applied Innovation provides a wealth of resources for entrepreneurs and inventors (many located at the Cove within University Research Park) looking for help in starting a company. At UCI Applied Innovation, you can identify a mentor and work with him or her regularly, network with like-minded entrepreneurs, review ideas with prospective investors, and evaluate commercialization opportunities with potential customers.

The Cove at UCI Applied Innovation offers daily opportunities to network with other entrepreneurs, investors, and industry experts. We encourage you to attend events and build relationships.

The ecosystem and entrepreneurial community being fostered at the Cove is playing a key part in the successes of UCI faculty innovators. For us, it has been indispensable. We connected with a few Cove residents and this resulted in seed funding that contributed to getting us off the ground.

– Michelle Khine
Professor, Biomedical Engineering
Director of Faculty Innovation, Samueli School of Engineering
Director of BioENGINE, UCI Applied Innovation
Founder, TinyKicks
Founder, Novoheart
UCI Applied Innovation provides access to UCI Experts in Residence, Licensing Officers, and Industry Contract Officers. We are also your connection to a community of businesses, investors and other entrepreneurs.

Develop Your Business Model, It’s the Map of Where You Want to Go.

A detailed and well-thought out business plan constitutes a thorough understanding of your business structure, target market, profit potential, competition, funding needs, resource management, and overall exit strategies. UCI Applied Innovation mentors can help you work on developing a solid business plan.

Pursue Funding Strategically—Money Makes Things Happen.

Technology/product commercialization is typically a capital-intensive process. There are many funding options to consider. You may need to present your opportunity to investors: venture capitalists, angel investors, and perhaps in the initial stages, friends and family.

Read more information:
p.28 Analyzing the Company’s Opportunities
p.34 Building a Funding Strategy

Network/Get Active:
The Cove @ UCI Applied Innovation: innovation.uci.edu/events
The Cove @ UCI Applied Innovation is home to Investors, VC Firms, Entrepreneurs, Marketing Firms, Mentors, UCI Affiliated Teams and myriad other partners that can help push your discovery to market.

**Structure is Essential. Get Counsel on your Legal Entity.**

A range of tax, accounting, business structure, corporate governance, and certain personal considerations drive the process of selecting an appropriate business entity. Forming a legal business entity is neither difficult nor expensive; however, you should consult with a qualified attorney as to which form of business entity is most appropriate.

**Compliance. It’s Not Scary, It’s Smart.**

As a UCI faculty member, you should consult with Academic Personnel, Conflict of Interest, and other relevant offices to develop a better understanding of the time and effort involved in creating a startup, and to help you avoid any pitfalls of acquiring new, external financial interests.

---

**Read more information:**

p.22 Building a Team  
p.43 Who to Contact

---

**Who to Contact:**

- **Legal Entity:** UCI Applied Innovation  
  949-824-2683

- **Compliance:** Conflict of Interest  
  coioc@research.uci.edu

- **Academic Personnel:**  
  acadpers@uci.edu
Secure the Right to Negotiate and Execute the License or Option Agreement

A technology transfer Licensing Officer in ITG will negotiate with an appropriate representative of the company to grant a license for your startup. In some cases, a short-term option agreement may be more cost-effective so that your company can demonstrate to potential investors that it has secured the rights to negotiate licensing for your technology.

UCI Applied Innovation’s connections between UCI researchers and the corporate community streamlined the commercialization process as they negotiated exclusive licenses for inventions developed by myself, and my colleagues here at UCI.

– Bruce Tromberg
Director, Beckman Laser Institute and Medical Clinic (BLI)
Professor, School of Medicine, Department of Surgery
Professor, Samueli School of Engineering, Department of Biomedical Engineering
Co-founder, Modulated Imaging, Inc.

Read more information:
p.30 Protecting Intellectual Property
p.33 Licensing

Who to Contact:
Licensing Officers @ Applied Innovation:
949-824-2683
http://innovation.uci.edu/about/research-trans-

When should I contact my Department Chair and Dean to discuss my proposed startup-related activities?
As soon as possible.

How many days per year may I dedicate to startup-related activities?
It depends. School of Medicine Health Sciences Compensation Plan participants may dedicate 21 days. Academic-year faculty may dedicate 39 days. Fiscal-year faculty may dedicate 48 days. Days dedicated to outside professional activities during vacation or unpaid leaves of absence do not count towards the time limit. If you are approaching your time limit, and want to spend more time on your startup activities, you should seek prior approval for exceeding the time limit. For more information, refer to the Conflict of Commitment (COC) section on page 22 or contact the Academic Personnel at acadpers@uci.edu.

For Conflict of Commitment purposes, what do I need to know about my role as a founder/co-founder of a startup company?
Founding a startup company is a Category I activity requiring annual disclosure (Form http://ap.uci.edu/wp-content/uploads/UCI-AP-3.doc collected by units each year) and prior approval (Form http://ap.uci.edu/wp-content/uploads/UCI-AP-2.pdf). If your role actively founding the company continues beyond your initial prior approval, you will need to request prior approval for as long as the founding activity continues. As your role changes over time - for example, no longer founding the company and moving into a board member role - your Conflict of Commitment obligations may also change. Contact Academic Personnel for advice about your specific situation at acadpers@uci.edu.

As a UCI employee, what type of role in the new company am I allowed to take?
University of California policies do not prohibit UCI employees from taking specific types of roles in outside companies, provided that these roles do not detract from or conflict with employee obligations and responsibilities to UCI. Additionally, certain UCI employees, primarily faculty members, are covered by the Conflict of Commitment Policies (APM 025 for general campus, APM 240 for Deans, APM 246 for Faculty Administrators - 100% Time, or APM 671 for Health Sciences Compensation Plan participants). These policies require annual reporting of outside professional activities and prior approval before engaging in certain outside professional activities. For example, a faculty member founding a startup who will be taking on a founding, co-founding, executive or managerial role should seek prior approval before engaging in these activities. For more information, refer to the Conflict of Commitment section on page 22. Contact the Academic Personnel at acadpers@uci.edu.

What is the limit on equity interests in an outside company for a UCI employee?
The University of California has not established a limit on the amount of equity interests you can acquire as an UCI employee. However, the dollar value and/or the percentage of issued and outstanding shares your equity interests represent may trigger Conflict of Interest disclosure and review requirements. For more information, refer to the Conflict of Interest (COI) section on page 26.

Will I have more disclosure requirements if I acquire a new financial interest?
You will most likely have additional disclosure requirements after you acquire a new financial interest. Your requirement to disclose will depend on a number of factors including but not limited to: the type/nature of your financial interest, whether or not your UCI research is related to the entity’s interests, and the types of sponsored research in which you are involved. The disclosure requirements are based on Conflict of Interest policies. For additional guidance, review the Conflict of Interest section on page 26. Contact the COI team at coioc@research.uci.edu.

How do I address my potential conflict of interest in research?
Each potential conflict of interest is unique. Therefore, the Conflict of Interest Oversight Committee (COIOC) considers multiple factors when determining whether or not additional safeguards are required to protect the objectivity of the research. Some factors the COIOC considers include but are not limited to: the study design, the status of the entity, and the nature of the investigator’s financial interest. For ideas on how to address the potential COI issues, review the COI Case Studies at research.uci.edu/compliance/conflict-of-interest/coi/case-studies.html or contact the COI team at coioc@research.uci.edu.

May I involve a student in my startup?
Yes, but prior approval may be required. If you have or will have supervisory or academic authority over the student you would like to involve, you must seek prior approval from your Department Chair using Form AP-2: http://ap.uci.edu/wp-content/uploads/UCI-AP-2.pdf. For more information, refer to the Conflict of Commitment section on page 22. Contact the Academic Personnel at acadpers@uci.edu.

What if I’m not ready to license the University of California technology(ies) that will be the basis of my startup company?
A variety of agreements are available to serve the particular needs of the company at different stages of its growth. Initially, a Letter of Intent may be sufficient. This type of short-term agreement provides for an exclusive negotiation period in exchange for limited financial consideration to UCI. This allows the startup to do any necessary due diligence.

FAQ’s*

*Answers featured herein do not supercede University policies. Always refer to University policies for the most current information.
around the IP and business opportunity, to refine its commercialization plan and to negotiate the license without being concerned that another party will also be negotiating with UCI. An evaluation license or option provides the company with the ability to conduct more in depth due diligence, including evaluating how the technology works in the company’s hands or performing proof of concept experiments to confirm the viability of the company’s plans. A Licensing Officer at ITG can meet with you and explain the different licensing arrangements to help you determine the best fit for your company based on its current circumstances.

**What happens if my company develops IP?**
It is anticipated that, during its research and development activities, a company will develop new IP that is distinct from the in-licensed UCI IP. If the new IP is generated independently by the company without UCI resources or UCI employees, the company will usually own the IP. If UCI funds, facilities, or employees were involved in generating the IP, UCI is likely to have an ownership position in the IP. If no UCI resources are used but company employees with UCI employees are co-inventors or co-authors, IP ownership may be shared with the company.

**If a faculty member participates in the company and develops IP, does UCI own it?**
University of California faculty are permitted to engage in certain outside professional activities, including consulting for companies. Companies are able to own IP developed by UCI faculty during permissible consulting activities that comply fully with applicable University of California policies. To learn more and to discuss best practices, please contact a Licensing Officer at ITG, or review the University of California’s Guidelines on Faculty Consulting and Intellectual Property, a copy of which is located at: [http://www.ota.uci.edu/industry-resources/faculty-expertise.html](http://www.ota.uci.edu/industry-resources/faculty-expertise.html).

UCI helped support the development of the technologies that would eventually be licensed to my company ALEKS, in 1997. Through the intervening years as ALEKS expanded to reach millions of students, and continued with the merger with McGraw-Hill Education in 2013, UCI has been vital to our continuing success.

– Jean-Claude Falmagne
Professor Emeritus, Cognitive Sciences School of Social Sciences
Chairman and Founder, ALEKS Corporation
Starting a Company: Key Considerations

### Best Practices For Starting A Business

**CONSIDER & CONSULT**

1. General startup company questions; including companies not licensing UCI intellectual property, contact cove@uci.edu
2. Consult Licensing Officer to assess licensing opportunities for specific UCI inventions including licensing the technology to a startup company
3. Consult Conflict of Interest if you, or a member of the company are a UCI researcher

**START DEFINING THE BUSINESS**

? Any UCI employees of the company? Consult Academic Personnel and Conflict of Interest
? Any UCI affiliated members of the company that are foreign nationals? Consult International Center
? Any UC intellectual property involved? Consult Applied Innovation Licensing Officer
? Any plans to conduct research at UCI related to company’s interest or sponsored by the company? Consult Conflict of Interest

**DECIDE TO CREATE THE BUSINESS**

**Faculty**
Submit Prior Approval to department chair, Dean and Vice Provost for signatures. Contact Academic Personnel if you have any questions

**Postdocs & Project Scientists**
Notify your Principal Investigator

**FORM BUSINESS ENTITY**

Update Conflict of Interest team to help manage conflict of interest disclosure requirements
If licensing intellectual property from UCI, contact Licensing Officer to establish necessary agreement
Consider Cove Resources for potential incubation and funding opportunities

*Contacts can be found on the inside back cover, or page 43.*
As a recap of the preceding section, the following is an outline of issues and concerns that will need to be addressed by the startup company. UCI Applied Innovation has a wide variety of resources and expertise that can be utilized to help you address these questions and issues. For more information, contact UCI Applied Innovation at cove@uci.edu.

**START DISCUSSIONS EARLY:**
We encourage you to contact ITG and UCI Applied Innovation early in the process to discuss your business and/or invention, how to protect the IP, and your thoughts about developing and commercializing the IP through a startup company.

**SEEK INPUT, NETWORK AND BUILD YOUR TEAM:**
UCI provides a wealth of resources for entrepreneurs and inventors looking for help to start a company, many located within UCI Applied Innovation. Identify a mentor and work with him or her regularly, network with like-minded entrepreneurs, review ideas with potential investors, and evaluate the commercial aspects with potential customers.

**PROTECT IP:**
Work with a Licensing Officer at ITG to evaluate the opportunity to file a patent application on the invention before it becomes public. A major asset of a startup company is its IP. Obtaining a patent after public disclosure may no longer be possible, particularly outside the United States.

**CHOICE OF LEGAL ENTITY:**
A range of tax, accounting, business structure, corporate governance, and certain personal considerations drive the process of selecting an appropriate business entity. Forming a legal business entity is not difficult or expensive; however, one should consult with a qualified attorney as to which form of business entity is most appropriate.

**ENSURE COMPLIANCE:**
As a UCI faculty member, you should also consult with Academic Personnel, Conflict of Interest, and other relevant offices to develop a better understanding of the implications of acquiring this new outside financial interest and to ensure compliance with University of California policies.

**DEVELOP YOUR BUSINESS MODEL:**
A detailed and well-thought out business model is often a key part of this phase through which you can develop a thorough understanding of target customers and applications, market potential, competition, funding needs, how you plan to develop the product, key management plans, and overall exit strategies.

**NEGOTIATE AND EXECUTE THE LICENSE OR OPTION AGREEMENT:**
A Licensing Officer at ITG will negotiate with the appropriate representative of the company to grant a license to your startup. In some cases, a short-term option agreement may be more cost-effective and may precede a license so that your company can demonstrate to potential funders that it has secured the rights to negotiate for a license to the technology.

**PURSUE FUNDING:**
Commercializing technology is typically a capital-intensive process. You’ll need to present your opportunity to people with the funds to help you make it happen: venture capitalists, angel investors and perhaps in the initial stages, friends and family.
Building a Team

Putting together a potent and cohesive group to form a startup company is an important first step. One of the most difficult aspects of creating a new business is determining who is in the business and establishing expectations concerning roles in, and commitments to, the company. If the inventor is the main motivator for the new company, then he or she must consider personal goals, family responsibilities, and professional commitments. If the inventor is not the motivator for the decision, then the business driver will have to determine who is involved, which usually includes the inventor in some role.

CHOOSING YOUR ROLE

Consider each founder’s role in the management team. Team members may be needed with strong domain expertise, product development, sales experience, and marketing know-how. Investors are usually interested in a company with a strong management team; they are unlikely to fund even the best ideas if the right team is not in place.

When choosing your role in the company, you should consider your involvement in the company, the current needs of the company, and your long-term plans for the company. You should be aware of University of California policies covering faculty involvement with outside entities.

The table on page 23 identifies requirements of Conflict of Commitment and Conflict of Interest policies based on the role or financial interests of the faculty member in the startup.

ININVOLVING A UCI FACULTY MEMBER

(Conflict of Commitment)

To honor your professional obligations to UCI as a UCI faculty member, you are required to request prior approval for certain outside activities described in the University of California policies covering Conflict of Commitment and Outside Professional Activities. These certain outside activities include but are not limited to: assuming a founding or co-founding role of a company, assuming an executive or managerial position outside of the University, and involving a student in your outside professional activity. Prior approval must be granted before engaging in the outside professional activity. In addition, faculty members are required to disclose annually for certain outside professional activities in an annual report.

For more information, please review the applicable Conflict of Commitment policy:
- APM 246 for Faculty Administrators - 100%
- APM 240 for Deans
- APM 671 for faculty participating in the Health Sciences Compensation Plan
- APM 025 for all other faculty covered by Conflict of Commitment policy.

Forms:
- Online Reporting System (School of Medicine only)

Requirements of Conflict of Commitment and Conflict of Interest Policies

<table>
<thead>
<tr>
<th>Role/Financial Interest</th>
<th>Conflict of Commitment</th>
<th>Conflict of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO/Officer/Executive or managerial position of company</td>
<td>Category I – requires prior approval of the Vice Provost. Subject to annual approval and reporting.</td>
<td>Disclosure may be required per State law and Institutional Review Board (IRB) COI Policy.</td>
</tr>
<tr>
<td>Founder</td>
<td>Category I – requires prior approval of the Vice Provost. Subject to annual approval and reporting.</td>
<td>Disclosure may be required per State law and IRB COI Policy.</td>
</tr>
<tr>
<td>Advisory Board Member/Member of Board of Directors</td>
<td>Category II – subject to annual reporting and time limits. If activity is managerial, it falls under Category I requiring prior approval of the Vice Provost.</td>
<td>Disclosure may be required if you are the Chair of the Advisory Board or Board of Directors per State law and IRB COI Policy.</td>
</tr>
<tr>
<td>Consultant</td>
<td>Category II – subject to annual reporting and time limits. If activity is managerial, it falls under Category I requiring prior approval of the Vice Provost.</td>
<td>Disclosure may be required per State law and IRB COI Policy. If also received income, disclosure may be required per Public Health Service (PHS) and National Science Foundation (NSF) COI Policies.</td>
</tr>
<tr>
<td>Employee</td>
<td>Category I – if salaried, requires prior approval of the Executive Vice Chancellor/Provost. Subject to prior approval and annual reporting</td>
<td>Disclosure may be required per State law and IRB COI Policy. If also received income, disclosure may be required per PHS and NSF COI Policies.</td>
</tr>
<tr>
<td>Research or administration of a grant outside of the University</td>
<td>Category I – requires prior approval of the Executive Vice Chancellor/Provost. Subject to prior approval and annual reporting.</td>
<td>Disclosure may be required if company sponsors research at UCI.</td>
</tr>
<tr>
<td>Equity or Ownership Interest</td>
<td>May or may not raise a conflict of commitment issue – determination on a case-by-case basis.</td>
<td>Disclosure may be required for all COI policies.</td>
</tr>
</tbody>
</table>

1 The COI disclosure requirements may apply based on the type of sponsor for your research project (non-governmental entity, NSF, or PHS) and if the research involves human subjects. In addition to the above scenarios, if you receive or will receive income from the company, regardless of your title/role in the company, you may be required to disclose.

1 See APM 025-14(a), Faculty titles subject to APM 025. All faculty holding appointments in the following title series are subject to this policy; however, faculty holding appointments of less than 50 percent time are not subject to the annual reporting and prior approval requirements: Professor, including Acting titles; Professor in Residence; Adjunct Professor; Professor of Clinical (e.g., Medicine); Health Sciences Clinical Professor; Clinical Professor of Dentistry; Lecturer or Senior Lecturer with Security of Employment; Lecturer with Potential Security of Employment. Please note that faculty holding titles in these series are subject to APM 025 if not participating in the Health Sciences Compensation Plan. Faculty participating in the Health Sciences Compensation Plan are subject to APM 671 and are not subject to APM 025.
INVOLVING A UCI ACADEMIC APPOINTEE

Other academic appointees who may become involved in a startup include Postdocs, Specialists, and Project Scientists. When hiring an academic appointee to work on a startup, it is important to remember that an academic appointment percentage at UCI should closely match the appointee’s time and effort commitment to the University. If an academic appointee has a 100% appointment at the University, the appointee should be dedicating time and effort appropriate for a 100% appointment.

Terms and conditions of employment at UCI for the following titles are available at the following links:
- Postdoctoral Scholars: Collective Bargaining Agreement
- Specialists: APM 330
- Project Scientists: APM 311

For additional information regarding special considerations related to inviting a UCI academic appointee to take part in a startup, contact Academic Personnel at 949-824-7175.

INVOLVING STUDENTS

Student involvement in outside companies, including faculty startups, may offer the student potential educational benefits. However, the relationship between faculty member and student must be protected from influences or activities that may interfere with learning consistent with the goals and ideals of UCI (see the Faculty Code of Conduct, APM 015). A faculty member involving a student in outside activities has the responsibility to ensure that the student’s participation does not interfere with the student’s academic obligations.

If the faculty member has, or expects to have, academic responsibility (instructional, evaluative, or supervisory) for the student, the faculty member must obtain prior written approval from the Department Chair using Form AP-2, http://ap.uci.edu/wp-content/uploads/UCI-AP-2.pdf, before involving a student in an outside professional activity regardless of whether the faculty member is compensated for or has a financial interest in the activity. The involvement of a student in the outside professional activity of a faculty member must not affect, positively or negatively, the faculty member’s evaluation of the student’s performance in any other context. For more information, please review the applicable Conflict of Commitment policy:
- APM 246 for Faculty Administrators - 100%
- APM 240 for Deans
- APM 671 for faculty participating in the Health Sciences Compensation Plan
- APM 025 for all other faculty covered by Conflict of Commitment policy.

For additional Note that student visas, as well as certain other visa types provided for university employees, are generally not transferable to an outside company for employment purposes. Transferring some visas can also be prohibitively expensive for a startup. Please be sure to consult appropriate counsel for assistance.

CONFLICT OF INTEREST (COI) OVERSIGHT MEMBERS FOR GRADUATE STUDENTS

One good way to help reduce the potential for a conflict of interest is to appoint a non-conflicted faculty member, “COI Oversight Member,” to a graduate student’s research/thesis committee if the student is involved in research related to their faculty mentor’s financial interest. The COI Oversight Member is a non-voting Ex Officio member of the student’s research advisory and/or thesis/dissertation committee meetings who is aware of the COI issues and the relevant campus policies. This COI Oversight Member is also required in cases where the Chair, Research/Thesis Advisor or other member of the committee has a financial interest in an outside entity that constitutes a conflict of interest that could potentially harm the graduate student. The COI Oversight Member is appointed by the Dean of the Graduate Division.

The process of Graduate Division selecting the COI Oversight Member is as follows, the Graduate Dean will select the COI Oversight Member from a list of three nominees agreed upon by the student, the faculty research/thesis...
advisor, and the departmental representative. The departmental representative will submit a written request to appoint a COI Oversight Member to the Graduate Dean no less than two weeks prior to the date of the exam to allow a reasonable time for review. This request should include background information describing the circumstances of the possible conflict. The Graduate Dean will retain sole authority to appoint the COI Oversight Member. No exceptions to this requirement will be considered. Please make sure the three faculty members listed as possible oversight members are senate faculty and are not from the student’s home department.

For more information, contact Andrea Bannigan: alanders@uci.edu, 949-824-1244

INVOLVING FOREIGN NATIONALS
When building a team for your startup team, it’s important to think about employment options and employment eligibility. UC Irvine hosts a variety of international and domestic students, scholars and faculty. Foreign nationals may have certain restrictions for employment based on their visa status in the United States. An individual’s visa status may also impact their opportunity to participate in the startup team.

Note that student visas, as well as certain other visa types provided for university employees, are generally not transferable to an outside company for employment purposes. Transferring some visas can also be prohibitively expensive for a startup. Please be sure to consult appropriate counsel for assistance.

If there are questions about employment eligibility when building your startup team, please contact the UCI International Center at internationalcenter@uci.edu for further guidance. UCI International Center staff will be able to assist with foreign national employment based matters.

CONFLICT OF INTEREST (COI)
The primary goals of the COI team are to protect the objectivity of research and to help individuals manage their potential conflicts of interest. A conflict of interest is when a researcher’s outside financial interest(s) may compromise or appear to compromise the design, conduct, or reporting of their research projects. To facilitate the committee reviews of financial interests, the Conflict of Interest Oversight Committee (COIOC), a committee composed of UCI faculty members reviewing financial disclosures, encourages you to do the following in your financial disclosures:

1. Be transparent in describing your financial interest
2. Acknowledge the potential conflict of interest
3. Explain how you have mitigated the potential conflict

The best way to understand and manage the disclosure requirements created by your new financial interest is to meet with the COI team while you are first developing your plans for yourself, your company, and your UCI research. The COI team can help identify potential concerns from the COIOC and provide suggestions on how to best address those concerns. The majority of potential conflicts of interest can be managed and recommended for approval with appropriate planning.

For more information, please review the following helpful COI Resources:
• Case Studies: research.uci.edu/ref/conflict-of-interest/coi/case-studies.html
• Disclosure Chart: research.uci.edu/ref/conflict-of-interest/forms-references/disclosure-chart-printable.pdf

To schedule a meeting with the COI team, email: coioc@research.uci.edu.

Conflict of Interest Best Practices

<table>
<thead>
<tr>
<th>Researcher Considers Acquiring a New Financial Interest</th>
<th>Researcher Submits an Updated Disclosure for COIOC Review</th>
<th>COIOC Reviews Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>COI meets with Researcher to discuss:</td>
<td>Researcher notifies COI so COI can help them update their disclosure</td>
<td>COIOC evaluates steps taken to address COI concerns as described in the disclosure and makes recommendation</td>
</tr>
<tr>
<td>Types of financial interest (role, equity, etc.) &amp; UC policies</td>
<td>Research considers COI concerns while designing new studies in anticipation of COIOC review(s) in light of new financial interest</td>
<td></td>
</tr>
<tr>
<td>Plans for new financial interest</td>
<td>COI conducts pre-review to facilitate COIOC review and works with Researcher to address any concerns or provide clarifications</td>
<td></td>
</tr>
<tr>
<td>How it affects their research (disclosure requirements, study design changes)</td>
<td>Researcher describes steps taken to mitigate potential COI in disclosure forms</td>
<td></td>
</tr>
<tr>
<td>How to address COI concerns in existing research projects &amp; new proposals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refers to Academic Personnel if necessary for conflict of commitment</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Analyzing the Company’s Opportunities

**Is there a market for your product?** This is the most important question to answer – if you turn your technology into a product, will customers want to buy it? To answer this question, it is a good idea to survey as many potential customers as possible. Does your technology solve a problem they think they have? Is your value proposition strong enough that those customers will be willing to pay a sufficient amount for it? Have you identified the features and benefits that are most important to your potential customers? Once you have answered these questions to your satisfaction, you can turn to assessing the market size.

**MARKET SIZE, DYNAMICS AND POTENTIAL**
What is the market size? Is it growing, stable, or shrinking? When analyzing the market size, it is important to focus on the addressable market that the product will specifically benefit. (For example, the addressable market for a new high power, extremely bright LED bulb, is not likely to be the entire lighting industry, but rather, the automotive or entertainment industries interested in automotive headlights and stage lighting. This technology may be the wrong fit for residential or other uses.) Is the market controlled by a few players? If so, how will your company enter the market and/or overcome market barriers? Of the addressable market, what share can be obtained by your company?

**COMPETITION**
Now that you have identified and assessed the market size, the next step is to understand your competition in that market. Are there products already in the market that address the same general need? Is your product sufficiently differentiated from competing products and/or does it offer a significant advantage over existing products? If so, how is your technology better? Are there other companies that are developing technology that would directly compete with yours? If so, what is their stage of development and why is your technology better?

**IP PROTECTION**
Your IP should give you a competitive advantage. Based on your understanding of the market and your competitors: What is the best form of IP to protect the technology? Is broad protection possible to secure? Are any key intellectual property rights owned by someone else? If so, how will the startup acquire the necessary rights or re-design the technology to assure “freedom to operate”? Can the company employ multiple forms of IP rights, such as a combination of patents, trademarks, copyrights and, later in the company’s development, trade secrets, to strengthen and supplement protection of its products and services? Will it be more advantageous to treat certain aspects of an invention as a trade secret and not file a patent application?

**DEVELOPMENT NEEDS/RISKS**
What further research and development will be needed to get the technology ready for commercial sales? What are the key development milestones? How long will it take to achieve these milestones and how much funding is needed to achieve them? What are the development risks, including full failure points, and how do you anticipate mitigating these risks?

**REGULATORY ISSUES**
Are any regulatory approvals required? If so, what is the history of similar products obtaining approvals, have you sufficiently accounted for the length of time and funding in obtaining approvals and what is the risk that the approvals will not be secured?

**EXIT STRATEGIES**
Based on the amount of funding required to develop the technology for commercial sale, is it possible for investors to achieve their necessary rate of return? Please note that different funding sources have different needs when calculating their necessary return on investment. For example, the federal government would not expect any return on investment when awarding a grant. In contrast, venture capital firms each have a return they seek to achieve, which could be as high as ten times the invested funding. The required return on investment can vary, so it is important to research individual investors, when possible, in addition to market standards.
Protecting Intellectual Property

IP refers to a category of intangible property rights comprising primarily patents, trademarks, copyrights, and trade secrets.

DISCLOSURE AND ASSIGNMENT OF PATENTABLE INVENTIONS

As a condition of employment at the University of California, faculty, staff, and researchers are obligated to disclose all inventions to the University of California and to assign to it their rights over any possibly patentable inventions developed within the scope of their University of California employment. This is accomplished through signature of the Patent Acknowledgment.

To preserve patent rights, you should disclose inventions by submitting a Record of Invention to ITG before making any form of public disclosure, e.g., a paper, poster session or discussion with a colleague. ITG Licensing Officers make a preliminary evaluation of the Record of Invention. Factors such as patentability, benefit to the public, commercial potential, and patent rights of outside parties are considered in selecting cases to pursue further.

If ITG decides to proceed with filing a patent application, ITG authorizes and coordinates the process, and engages a patent attorney to draft the patent application. In doing so, the attorney will often work closely with you to complete the application.

The completed patent application is submitted to the United States Patent and Trademark Office (USPTO). At the time of filing of the application, you execute legal documents assigning the patent to the University of California pursuant to the inventor’s Patent Acknowledgment. After the application has been submitted to the USPTO, the whole patent process commonly takes at least three to five years.

Procedures differ for filing applications in foreign countries, and they are very costly. ITG recommends filing foreign patent applications only when the cost is likely to be recovered from a licensee. If a publication has been made after a U.S. patent application filing, a preliminary foreign filing date must be made within one year of the U.S. filing date in order to preserve rights in other countries.

The table on page 31 summarizes various types of IP ownership at the University of California.

| Patents | UCI employees, as a condition of employment, must disclose and sign patent rights to the University of California. The patent application process is administered by ITG and the University of California Office of Technology Transfer. If the invention resulted from unrelated outside work, UCI may decide that it does not have a right of ownership. |
| Copyrights | Ownership of the copyright in the work depends on the conditions and funding of the particular work. If classified as a “Work for Hire” or part of a sponsored research, the copyright belongs to University of California. If the work results from other intellectual activity, the copyright will generally belong to the individual. Administration of University of California-owned copyrights is carried out by the UCI’s Invention Transfer Group (ITG). |
| Trade Secrets | UCI generally does not assert rights to the “know-how” or a trade secret held by its faculty. UCI occasionally may maintain, transfer and/or receive confidential information under secrecy agreements. |
Licensing

The legal agreements to provide rights in UCI intellectual property to a company are handled by the Licensing Officers in the Invention Transfer Group. A faculty member and startup company can expect the following with regards to the licensing process:

1. A company must be formed. UCI will not license to an individual. The startup company must demonstrate that it has the resources to develop the product in a timely manner consistent with the stage of the technology.

2. Under a license agreement, UCI will require the startup company to pay patent costs, licensing fees, and royalty on sales of a product, consistent with licensing practices for any other commercial entity. Financial terms of the license are based on comparable market rates, however UCI often accepts equity in order to help reduce initial fees for startup licenses.

3. UCI will not negotiate with the faculty member or other UCI employee, therefore the startup company should find appropriate representation to negotiate with the Licensing Officer at ITG. This may be another person working for the startup who does not have a conflict with the university or it could be someone, such as an attorney, hired specifically to represent the startup company in the negotiation.

4. The startup company will be treated similarly as any other university licensee. If the startup company fails to meet diligence provisions, make financial payments, or otherwise not meet its obligations under a license agreement, the company risks losing the license.

The Licensing Officers at ITG complete several startup licenses every year and are well versed in working with startups. They utilize template agreements and can address areas of concern for the startup. Once the startup company is ready to discuss a license agreement, contact the Licensing Officer managing the technology of interest for an initial meeting.

I am grateful to start companies at this time at UCI because UCI Applied Innovation provides extensive services that allow me to navigate through this unfamiliar territory.”

– Weian Zhao, Ph.D.
Associate Professor,
Sue and Bill Gross Stem Cell Research Center
Chao Family Comprehensive Cancer Center
Edwards Lifesciences Center for Advanced Cardiovascular Technology
Department of Biomedical Engineering
Department of Biological Chemistry
Department of Pharmaceutical Sciences
University of California, Irvine
Founder, Velox Biosystems
Building a Funding Strategy

Commercializing technology can be a capital intensive process; entrepreneurs often need to raise funds from investors and other sources. You should research each funding source carefully before pitching to them to confirm a match with your interests and needs. Be sure to adjust your pitch to address each investor’s interests. Investors and grant programs will typically focus on specific markets or will provide funding only at certain stages of the company’s lifecycle. If your company does not match an investor or other funding source’s interests, there is little chance of attracting an investment. Common sources of early stage funding for a startup company include:

1. **Organic Growth.** Entrepreneurs can also grow companies slowly based on sales, without the need to raise external funds. Organic growth can be a reasonable strategy for certain ventures. Typically, however, UCI innovations are at such an early stage of development that additional funds are necessary to move them from the lab to market.

2. **Proof of Product Grants.** Proof of Product (POP) Grants are part of UCI Applied Innovation’s suite of programs and initiatives to Bridge Innovation Gaps (BIG), supporting UCI projects in the early stages to effectively partner with industry to translate into commercially viable products. POP Grants provide funds to assist in developing technologies with a focus on rapid assessment of commercial feasibility. The Grants are awarded to Principal Investigators to further the development of the technology so that it is more attractive to a startup/licensee. Ranging up to $125,000 per selected project, POP Grants trigger and help focus the entrepreneurial spirit among campus innovators. For more information visit: [http://innovation.uci.edu/programs/pop-grants/](http://innovation.uci.edu/programs/pop-grants/).

3. **Federal Grants.** The U.S. government provides innovation research grants to small companies, which can be great and non-dilutive sources of initial capital. The Small Business Innovation Research (SBIR) program is sponsored by eleven federal agencies, including the National Institute of Health (NIH), National Science Foundation (NSF), and Department of Defense (DoD). SBIR funds can be used for just about any industry: life science, physical sciences, information technology, or even education technology. A sister program; Small Business Technology Transfer (STTR) allows for R&D to be performed in partnership with a university or non-profit research institution.

   **Resources:**

   For more information about applying to these funding opportunities contact Industry Sponsored Research at cove@uci.edu. For more information about managing potential conflicts of interest related to these research plans, contact the COI team at: coioc@research.uci.edu.

4. **Friends and Family.** During the earliest stages of company formation, entrepreneurs often use their own funds, or funds provided by friends and family, to get the company off the ground. A “friends and family” round can provide critical seed funding. However, take care to assure that what the company provides in exchange for the funding will not unduly interfere with future funding opportunities.

5. **Seed Funding.** Seed funding refers to money used to start the company. Most seed funding comes from family, friends and the entrepreneur. There are also specific seed funds that will invest small amounts into a business to help it get started.

   One example is the Cove Fund, headquartered in the Cove at UCI, which provides funding for promising new ventures that emerge from the Orange County ecosystem. This UCI independent fund focuses on technology and life science opportunities that are potentially rapidly scalable. Preference will be for companies with the majority of their operations in Orange County. The Fund will be able to co-invest with local angel groups, incubators/accelerators that have a relationship with Applied Innovation. The maximum investment in an individual company is $250,000 from the Fund. Co-investment from other parties can result in significant additional funds. For more information, visit: [https://www.covefund.com/](https://www.covefund.com/).

6. **Angel Investing.** Angel investors are typically affluent individuals who have a personal interest in funding new companies. They are often willing to invest at earlier stages than venture capitalists, often with smaller amounts of funding in exchange for equity positions. The best angel investors for your company are ones with ties or direct experience in your market or industry, who can offer your start up more than just money. Some angels will form into groups to share research, vet opportunities and pool investments. These angel groups or networks allow your company to pitch to many angels at the same time.

7. **Venture Capital.** Typical venture capital firms (VCs) invest after the seed funding round (i.e. during Series A, B or C) in exchange for an equity stake in the company. VCs raise substantial funds from other sources, such as institutional investors. They then invest the funds in high growth potential companies. VCs are typically hands-on, interacting with the startup’s management team and will often help locate and place senior management into the startup. VCs also typically require relatively high annualized return on the funds used to make investments.
Use of University Facilities/Resources
UCI is a public institution, heavily subsidized by the state and federal taxpayers and tasked with the performance of academic and scholarly research. However, private companies are allowed to directly use or access UCI resources when UCI has specifically identified that resource as available for use by external users.

On-Campus Incubator

The Cove
UCI has on-campus incubator spaces where startup companies can apply to lease offices and basic lab space, including:

The Cove
Contact: 949-824-2683 | cove@uci.edu
The Cove is 46,000 square feet of state-of-the-art technological facility located in University Research Park that houses office, lab, and event space. It is home to UCI Applied Innovation, whose mission is to facilitate connections between UCI and industry, including: entrepreneurs seeking access to university inventions and talent, large corporations looking to tap the school’s research capabilities, and investors wanting to financially support promising new companies. Additionally, UCI Applied Innovation is working to cultivate an “innovation district” in the heart of Orange County, producing more start-ups, more scale-ups, and, ultimately, a world-class entrepreneurial ecosystem.

Beckman Laser Institute Photonic Incubator
Contact: Deborah Birnie
949-824-8517 | dbirnie@uci.edu
The Beckman Laser Institute (BLI) has established a Photonic Incubator to utilize photonic (light) technologies (lasers, optics, detectors, etc.) in the development of new biomedical systems for medical diagnostics, therapeutics, and cellular/molecular analysis. BLI’s Photonic Incubator offers affordable office and laboratory space and access to the existing facility’s core laboratory areas, scientific and medical expertise, programs, and extensive corporate contacts in the area of medical photonics. The incubator fosters an environment that supports start-up companies created by the collaboration of BLI researchers and affiliated professionals and provides a unique, high-impact resource for technology transfer.

CallIT2 TechPortal
Contact: Jacqueline Myers
949-824-6046 | info@callit2.uci.edu
TechPortal, a business technology incubator in the Calit2 Building, serves as a gateway to commercial viability for UCI-based startup companies. TechPortal offers affordable space, access to facilities and services, and mentoring programs and expertise to help new companies gain traction in the marketplace. TechPortal can house up to seven companies in its 1460 square feet of space and Calit2 offers the perfect combination of lab space, experts, programs, and facilities. Its wet and dry lab spaces provide options for a wide range of startup companies.

Company Access to UCI Service/Equipment
The company should contact the manager or fiscal officer of the department with the service or equipment the company is interested in using to determine if it has been approved for external use. Please note that any UCI employee with a financial interest in the company interested in establishing a Sales & Services Agreement with UCI must recuse themselves from the process. Instead, a company employee without a UCI affiliation should negotiate the Agreement with UCI to avoid violating the California State Law.

Established Sales & Services Activity
If the resource has been approved for external use, the department can initiate a Sales & Services Agreement specific to the company. Please contact the facility directly to determine whether or not it is available for external use.

Potential Sales & Services Activity
If the resource has not yet been approved, please contact the Director of Intellectual Property Administration, Kevin Kennan (kkennan@uci.edu), for guidance on whether or not the UCI equipment or service you are interested in could become an established Sales & Services Activity.
UCI Commercialization Programs

Included UCI Commercialization programs are designed to support PI’s, staff and students in the translation of research into market use. They are focused on technology readiness in effort to address gaps in the translation of UCI research and IP into commercially viable products/services.

Wayfinder
Contact: 949-824-2683 | wayfinder@uci.edu
Wayfinder is a program for UCI-affiliated startups that is designed to accelerate venture development. Teams in Wayfinder have access to guidance and mentorship from UCI Applied Innovation’s Experts-in-Residence Network, learning experiences through workshops and office hours, work space and meeting rooms at the Cove, networking and exposure opportunities, and funding resources. As a central part of UCI Applied Innovation’s entrepreneurial ecosystem, Wayfinder teams may experience additional tangential benefits and enrichment opportunities that result from their enhanced engagement with the community. For more information, visit: http://innovation.uci.edu/programs/wayfinder-incubator/.

I-Corps
Contact: 949-824-2683 | i-corps@uci.edu
I-Corps is an NSF funded program that trains individuals to broaden the impact of basic-research projects and develop effective solutions to customer problems. The mission is to increase research-based technology commercialization capabilities and activities across Orange County, CA. The program provides the infrastructure, resources, advice, networking opportunities, training, and funding for motivated teams to assess their commercial opportunity. For more information, visit: http://innovation.uci.edu/programs/i-corps/.

Tech Surge
Contact: 949-824-2683 | wayfinder@uci.edu
Tech Surge is a special track of the UCI New Venture Competition focused on the translation of UCI-generated innovations. To qualify for this track, a team must use UCI intellectual property as a core element of the business it is entering into for the New Venture Competition. Winners of the Tech Surge competition earn prize money to further their commercialization pathway and are automatically invited to join the Wayfinder incubator program @ UCI Applied Innovation. For more information, visit: http://innovation.uci.edu/programs/tech-surge/.

Use of UCI Name and Logo

The Regents of the University of California is the State of California Constitutional Corporation that runs and manages the University of California. The Regents own and control the University’s names and logos. As a public, state entity, the University of California is prohibited from endorsing any specific company, product or service. As a result, the use of the University of California names and logos are restricted and cannot be used to imply, directly or indirectly, that the University supports, favors or endorses any commercial product. If a faculty member is involved in your company, it is appropriate to identify them as a professor at UCI as long as the statement is factual and does not imply endorsement.
Dr. David Cuccia is the CEO and CTO of Modulated Imaging, a startup based in Irvine, CA that is focused on employing a UCI-patented optical imaging technology, spatial frequency domain imaging (SFDI), toward helping diabetic patients avoid complications, such as ulcers and amputations.

2002 - 2006: The seeds for Modulated Imaging were planted in 2002, when David, then an undergraduate in Physics at UC Irvine, began exploring new light-based ways to more accurately image and measure the health of tissue. With the help of his mentors, Dr. Bruce Tromberg and Dr. Anthony Durkin at the Beckman Laser Institute, David developed a new imaging technique and Spatial Frequency Domain Imaging (SFDI) was born.

David was excited about the potential of SFDI and made it the subject of his doctoral dissertation in Biomedical Engineering from 2002-2006. The facilities of the Beckman Laser Institute and the UCI IRB review committee were both significant contributors to David's success in building and medically validating SFDI technology.

2006 - 2012: In 2008 after receiving his Ph.D., David began to build the Modulated Imaging startup team and product development of his SFDI technology. The Modulated Imaging startup was originally housed within the Photonic Incubator at the Beckman Laser Institute at UC Irvine. Once Modulated Imaging was incorporated, David and all the UCI affiliated personnel with financial
interests in Modulated Imaging worked closely with the Conflict of Interest (COI) team to address the conflict of interest concerns. By working with the COI team, a plan to address COI concerns (including those related to data collection, analysis, and reporting) was developed which allowed the UCI research to continue. The COI Plan has continued to be updated and modified as the company has developed over the years.

David credits UCI for much of Modulated Imaging’s early funding success; most importantly, through UCI’s Small Business Innovative Research Program. David and Modulated Imaging applied for and were awarded SBIR grants totaling over $7 million that helped fund his research technology development.

In 2010, Modulated Imaging introduced its first generation Ox-Imager™ device, and made it available to a select group of customers within the research community, including researchers from the Beckman Laser Institute and Dartmouth College. Modulated Imaging also entered into a Letter Agreement with UCI for three patents that were the basis for their technology. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.

2012 - Today: Through continued and expanded research collaborations and funding from SBIR/STTR awards, over $11M to date, Modulated Imaging made advancements from the initial product. The SBIR/STTR funding also required refining the conflict of interest mitigation plan as some of the funding was subcontracted to UCI. In 2012, Modulated Imaging released their second-generation research product, Reflect RS. The current version of the Modulated Imaging research platform is a true “turnkey” research instrument and is now found in corporate research laboratories, as well as in many internationally recognized universities.

After several years of successful SBIR/STTR funding, Modulated Imaging moved out of the BLI Photonics Incubator space in 2014 and signed a license with UCI for the 4 technologies in the Letter Agreement as well as three additional patents. The company expanded to its first commercial space in San Juan Capistrano, and quickly outgrew this location.

Today, Modulated Imaging company has grown and operates in a 6,000-sq. ft. building in Irvine, California, that includes office space, and separate areas dedicated to lab research and device production. In August 2016, Modulated Imaging secured their first round of private financing, jointly backed by the Cove Fund and Hamamatsu Corporation. In December 2016, Modulated Imaging received FDA clearance for their first medical device, Ox-Imager CS. Finally, in August 2017, the company secured Series A financing to help with the planned clinical studies, point-of-care device development, FDA submissions and market/customer development.
A Message from the Chief Innovation Officer at UCI Applied Innovation and the Vice Chancellor for Research at UCI

Creating a new company is an exciting and complex process that may generate new opportunities. We hope this guide provides a clear starting point for engaging you in conversations about your entrepreneurial journey with the Invention Transfer Group (ITG), UCI Applied Innovation, and other campus resources. This handbook is just one resource we have at UCI to help UCI inventors and aspiring entrepreneurs develop their ideas and possibly create companies or engage with industry about their innovations.

To access the many UCI resources, we strongly encourage you to contact UCI Applied Innovation and ITG staff, who have experience supporting inventors and steering them to needed resources, including their peer entrepreneurial academic researchers and contacts in the business community.

Our offices are committed to supporting the entrepreneurial efforts of our campus and working collaboratively with other offices to facilitate the process.

Richard Sudek
Chief Innovation Officer and Executive Director,
UCI Applied Innovation

Pramod Khargonekar
Vice Chancellor for Research

Quick Contacts

UCI Contacts:
UCI Applied Innovation:
Phone: 949-824-2683 | Email: cove@uci.edu
Events: innovation.uci.edu/events

Conflict of Interest:
Nadia Wong, Conflict of Interest Administrator
Phone: 949-824-0012 | Email: nadiaiw@uci.edu

Industry Sponsored Research:
Kevin Kennan, J.D.,
Director, Intellectual Property Administration & Industry Sponsored Research
Phone: 949-824-2683 | Email: kkennan@uci.edu

Invention Transfer Group:
Alvin Viray, Esq., Associate Director
Phone: 949-824-2683 | Email: aviray@uci.edu

Incubators:
UCI Beckman Laser Institute Photonic Incubator:
Deborah Birnie
Phone: 949-824-8517 | Email: dbirnie@uci.edu

Calit2 (Tech Portal):
Jacqueline Myers
Phone: 949-824-6900 | Email: info@calit2.uci.edu

The Cove:
Phone: 949-824-2683 | Email: cove@uci.edu